NOSORIX Trademark

Trademark Overview


On Monday, September 8, 2003, a trademark application was filed for NOSORIX with the United States Patent and Trademark Office. The USPTO has given the NOSORIX trademark a serial number of 78297277. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, February 22, 2013. This trademark is owned by GlaxoSmithKline Biologicals S.A.. The NOSORIX trademark is filed in the Pharmaceutical Products category with the following description:

vaccines for human use

General Information


Serial Number78297277
Word MarkNOSORIX
Filing DateMonday, September 8, 2003
Status710 - CANCELLED - SECTION 8
Status DateFriday, February 22, 2013
Registration Number3115935
Registration DateTuesday, July 18, 2006
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 25, 2006

Trademark Statements


Certificate of Correction for RegistrationIn the Statement, Column 2, line 1 through 4 "priority claimed under sec 44 (d ) on united kingdom application no. 2339861, filed 8-5-2003, reg no. 003607496, dated 4-11-2005, expires 4-27-2014" should be deleted, and priority claimed under sec. 44 ( d) on United Kingdom Application No.2339861, Filed 8-5-2003, Reg. No. 2339861, Dated 8-5-2003, Expires 8-5-2013 is inserted.
Goods and Servicesvaccines for human use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, February 22, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxoSmithKline Biologicals S.A.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressRixensart B-1330
BE

Party NameGlaxoSmithKline Biologicals S.A.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRixensart B-1330
BE

Party NameGlaxoSmithKline Biologicals S.A.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRixensart B-1330
BE

Trademark Events


Event DateEvent Description
Friday, March 15, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 22, 2013CANCELLED SEC. 8 (6-YR)
Wednesday, February 20, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 20, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 13, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, December 3, 2009ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 3, 2009TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 12, 2007CORRECTION UNDER SECTION 7 ¿ PROCESSED
Friday, March 23, 2007ASSIGNED TO PARALEGAL
Thursday, March 8, 2007SEC 7 REQUEST FILED
Thursday, March 8, 2007PAPER RECEIVED
Tuesday, July 18, 2006REGISTERED-PRINCIPAL REGISTER
Tuesday, April 25, 2006PUBLISHED FOR OPPOSITION
Wednesday, April 5, 2006NOTICE OF PUBLICATION
Friday, March 3, 2006LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, February 24, 2006ASSIGNED TO LIE
Friday, February 10, 2006APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 7, 2006AMENDMENT FROM APPLICANT ENTERED
Thursday, November 17, 2005CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 17, 2005TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 7, 2005INQUIRY TO SUSPENSION E-MAILED
Thursday, July 7, 2005SUSPENSION INQUIRY WRITTEN
Wednesday, May 18, 2005LIE CHECKED SUSP - TO ATTY FOR ACTION
Thursday, November 4, 2004LETTER OF SUSPENSION E-MAILED
Thursday, November 4, 2004SUSPENSION LETTER WRITTEN
Thursday, October 14, 2004ASSIGNED TO LIE
Wednesday, September 1, 2004TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 5, 2004NON-FINAL ACTION E-MAILED
Thursday, March 4, 2004ASSIGNED TO EXAMINER

Related Keywords


nosorix human vaccines